Used in targeted cancer therapy, particularly for gastrointestinal malignancies such as colorectal and pancreatic cancers. It binds specifically to the MUC5AC glycoprotein, which is overexpressed in certain tumor tissues but has limited expression in normal tissues, enabling selective targeting. This specificity helps in reducing damage to healthy cells during treatment. The antibody is being investigated in clinical trials for its efficacy in imaging tumors and delivering therapeutic agents directly to cancer cells. It also supports diagnostic applications by aiding in the detection of MUC5AC-positive tumors through immunohistochemistry and other detection methods.